BioMarin's Vimizim Gets NICE Final Nod
This article was originally published in Scrip
BioMarin Pharmaceuticals' enzyme replacement therapy, Vimizim (elosulfase alfa), has been given the thumbs up by NICE, the UK's health technology appraisal body, for use on the National Health System to treat mucopolysaccharidosis patients.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.